$275 Million is the total value of Fairmount Funds Management LLC's 20 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 36.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Buy | INSMED INC | $36,177,000 | -1.0% | 1,313,607 | +2.3% | 13.16% | -12.4% |
| ZGNX | Sell | ZOGENIX INC | $29,503,000 | -13.3% | 1,942,259 | -1.4% | 10.73% | -23.3% |
| New | NUVALENT INC | $20,625,000 | – | 914,614 | +100.0% | 7.50% | – | |
| ALLK | Buy | ALLAKOS INC | $18,566,000 | +42.9% | 175,362 | +15.2% | 6.75% | +26.4% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $18,006,000 | +129.8% | 316,952 | +78.0% | 6.55% | +103.2% |
| ARGX | Sell | ARGENX SEsponsored adr | $17,710,000 | -14.9% | 58,644 | -15.2% | 6.44% | -24.7% |
| Sell | TRILLIUM THERAPEUTICS INC | $15,563,000 | +79.0% | 886,281 | -1.1% | 5.66% | +58.3% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $15,530,000 | +2319.0% | 944,092 | +2590.3% | 5.65% | +2039.0% |
| COGT | COGENT BIOSCIENCES INC | $13,111,000 | +3.7% | 1,558,975 | 0.0% | 4.77% | -8.3% | |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $12,792,000 | +15.3% | 2,508,237 | -1.0% | 4.65% | +2.0% |
| TIL | INSTIL BIO INC | $12,046,000 | -7.5% | 673,905 | 0.0% | 4.38% | -18.2% | |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $9,607,000 | -27.0% | 389,588 | -23.0% | 3.49% | -35.4% |
| New | TYRA BIOSCIENCES INC | $8,778,000 | – | 499,040 | +100.0% | 3.19% | – | |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $8,455,000 | – | 1,099,489 | +100.0% | 3.08% | – |
| New | ASTRIA THERAPEUTICS INC | $8,060,000 | – | 911,736 | +100.0% | 2.93% | – | |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $6,923,000 | -33.0% | 416,817 | -1.7% | 2.52% | -40.8% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $6,370,000 | -13.4% | 250,000 | +19.0% | 2.32% | -23.4% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $6,183,000 | -70.7% | 187,598 | -40.0% | 2.25% | -74.1% |
| KROS | KEROS THERAPEUTICS INC | $5,908,000 | -6.8% | 149,333 | 0.0% | 2.15% | -17.6% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $5,078,000 | +825.0% | 926,602 | +1003.8% | 1.85% | +717.3% |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -888,980 | -100.0% | -3.52% | – |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -4,092,166 | -100.0% | -3.55% | – | |
| RACA | Exit | THERAPEUTICS ACQUISITION COR | $0 | – | -864,214 | -100.0% | -3.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.